Fairtility

Fairtility is powering in vitro fertilization (IVF) through transparent artificial intelligence to improve outcomes. It allows to reduce the number of IVF cycles to live birth, minimize the emotional, physical and financial burden on prospective parents, and enable collaborative discussions between clinicians and patients. CHLOE (Cultivating Human Life through Optimal Embryos) is a transparent AI-based decision support tool that provides clinicians with complete visibility into the clinical and laboratory parameters that make up data output to help improve IVF outcomes. Beginning with CHLOE EQ, a proprietary embryo grading platform, Fairtility is on a path to expand CHLOE's application to span the full IVF journey, from infertility cause assessment through transfer optimization.

Fairtility has raised $18.5M in total funding across 3 rounds. The company is currently at the A stage. Key investors include Kreos Capital, Gurnet Point Capital, Nacre Capital.

Fairtility was founded in 2019 by Eran Eshed (Co-founder & CEO), Dr. Assaf Ben-Meir (Co-founder & CMO), Itay Erlich (Co-founder (No longer with the company)).

Fairtility operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, with core technologies in Platforms & Interfaces, Software, Artificial Intelligence, Computer Vision, Data Storage, Cloud. Target customers: Consumers, Demographics & Family, Women, Healthcare & Life Sciences, Healthcare, Laboratories, Providers, Patients.

Fairtility is based in HaMelacha St 8, Tel Aviv-Yafo, Israel, Center District.